|
Invited Speakers:
|
|
Marc CEUPPENS
M.D., MBCPM, KUL, Head of Drug Safety, TibotecPhilippe DETILLEUX
DVM Université de Liège, Ph.D. in veterinary pathology, Iowa State University, Head Drug Safety Evaluation,Sanofi-Aventis, France Dominique DUBOIS
M.D., KUL, FFPM, Health Economics, Johnson & Johnson Pharmaceutical Services Jacques DUMONT
M.D., Ph.D., ULB, Chairman of the Board Euroscreen Maria Christina KOSTER
M. Pharm., Ph.D. in pharmacology, Vigilex,Rotterdam, Netherlands Véronique THYBAUD
Ph.D. in toxicology, University of Paris, Director, Genetic Toxicology, Sanofi-Aventis, France Guy VANDENHOVEN
M.D., K.U.L., Ph.D., FFPM, Medical Director, AstraZeneca, Belgium Jan Willem VAN DER VELDEN
M.D., FFPM, University of Leiden, Vice-President global drug safety and pharmacovigilance, PharmaNet Eric VAN GANSE
M.D., Ph.D., FRCP, Associate professor of pharmacoepidemiology, Hôpital Edouard Herriot, Lyon, France René VERLOES
M.D., Ph.D., lecturer in preclinical safety of medicines VUB, Associate director, regulatory management, and Expert in toxicology worldwide, Tibotec
|
|